1. Home
  2. NTZ vs VERU Comparison

NTZ vs VERU Comparison

Compare NTZ & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natuzzi S.p.A.

NTZ

Natuzzi S.p.A.

N/A

Current Price

$2.70

Market Cap

34.3M

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.32

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTZ
VERU
Founded
1959
1971
Country
Italy
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
36.8M
IPO Year
1998
1996

Fundamental Metrics

Financial Performance
Metric
NTZ
VERU
Price
$2.70
$2.32
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
5.5K
49.2K
Earning Date
04-13-2023
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.36
52 Week High
$5.50
$4.59

Technical Indicators

Market Signals
Indicator
NTZ
VERU
Relative Strength Index (RSI) 50.72 41.21
Support Level $2.66 $2.15
Resistance Level $3.20 $2.70
Average True Range (ATR) 0.27 0.11
MACD -0.02 -0.02
Stochastic Oscillator 70.14 23.53

Price Performance

Historical Comparison
NTZ
VERU

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: